Immungenetics AG: Immungenetics AG sets up a cooperation with Prof. Jens Pahnke, M.D. Ph.D., E.F.N., for the further development of the new 'Alzheimer's gene'
(firmenpresse) - Immungenetics AG / Key word(s): Health/
Immungenetics AG: Immungenetics AG sets up a cooperation with Prof.
Jens Pahnke, M.D. Ph.D., E.F.N., for the further development of the
new 'Alzheimer's gene'
DGAP-Media / 02.09.2011 / 08:27
---------------------------------------------------------------------
Immungenetics AG sets up a cooperation with Prof. Jens Pahnke, M.D. Ph.D.,
E.F.N., for the further development of the new 'Alzheimer's gene'
Today, Immungenetics AG has announced that the company entered into a
long-term cooperation with Professor Jens Pahnke of the University of
Rostock. As part of this collaboration Immungenetics AG and Prof. Pahnke
will jointly work on the research and commercialization of genetic
diagnosis, prognosis and treatment markers. Furthermore, they will work on
active compounds to improve the treatment of neurodegenerative diseases. 'I
am very glad to enhance our research with a competent and innovative
industrial partner who will support us in the development and application
of our recent results,' says Prof. Pahnke. Together with his team, Prof.
Pahnke has continuously delivered research results that were implemented in
the cooperation with various industrial partners. The cooperation with
Immungenetics AG is aimed at strengthening research activities in the early
stages of research and development by establishing strong scientific
synergies between Immungenetics AG and his research group and at the same
time boosting the use for the public. 'This is an important strategic
investigation for Immungenetics AG because the cooperation with Prof.
Pahnke enables us to benefit from his internationally acknowledged
expertise on a long-term basis and, thus, expands the indications we have
been addressing so far into the important field of neurodegenerative
diseases,' Moritz v. Grotthuss says, CEO of Immungenetics AG.
In a first project, the cooperation will investigate the application of
Thiethylperazine (Torecan(R)) and Thiethylperazine derivatives to activate
the brain's ABC transporter ABCC1 for the treatment of neurodegenerative
disorders. This project will set up a new treatment strategy to delay the
course and the onset of Alzheimer's disease for several years and, thus,
not only helps patients but at the same time will save considerable health
care expenses. It's is the second indication for a known drug which was
established in the 1960ies for vomiting and nausea. Recently, Prof. Pahnke
published this new mechanism for sporadic Alzheimer's disease (99% of all
AD patients) in a widely recognized article in the US-American scientific
'Journal of Clinical Investigation', October 2011 edition (available online
from September 1st, 2011, http://www.jci.org). Moreover, the function of
the ABCC1 will be employed for the use as an early diagnostic and therapy
monitoring marker of Alzheimer's and Parkinson's disease.
The further development of the new compounds and their commercialization in
the setting of early diagnosis, preventive therapy and also therapy
monitoring will be accomplished in a closed cooperation with strong
partners from the pharmaceutical industry.
Contact
Immungenetics AG
Moritz v. Grotthuss (CEO)
Tel. +49 (0)381 128 5224
Mail: news(at)immungenetics.com
Web: www.immungenetics.com
Prof. J. Pahnke, MD, PhD, EFN
Universität Rostock, Neurodegeneration Research Lab (NRL)
Tel: +49 (0)381 494 4700
Web: http://www.nrl.uni-rostock.de
Prof. Jens Pahnke, M.D., Ph.D, E.F.N., studied Medicine and Molecular
Biology at the University of Greifswald. After spending a few years as a
researcher at the University of Zurich, he was offered the Professorship
for Neurodegeneration at the University of Rostock in 2005. He is a
neuropathologist and head of the Neurodegeneration Research Lab (NRL) at
the Center for Mental Diseases in Rostock which specializes in basic and
translational research on Alzheimer's disease (AD) and other
neurodegenerative disorders. His discovery of a new mechanism of sporadic
AD was highly acclaimed. Prof. Pahnke is also member of the German Center
for Neurodegenerative Diseases [Deutsches Zentrum für Neurodegenerative
Erkrankungen, DZNE].
Immungenetics AG was founded by Prof. Saleh Ibrahim M.D., Ph.D. in
cooperation with engage Key Technology Ventures AG. Immungenetics AG
specializes in genetic associations to allow for improved recommendations
regarding the prognosis and treatment of various autoimmune diseases, with
a special focus on multiple sclerosis or rheumatoid arthritis. These
genetic associations are employed to develop respective active ingredients.
Immungenetics AG have their headquarters in Rostock as well as offices in
Lübeck, they work closely together with the University of Rostock, the
University Hospital of Rostock, the University Hospital of
Schleswig-Holstein (Campus Lübeck) and the company Gensoric GmbH.
Immungenetics AG receives funds from the German Federal Ministry for
Education and Research's program 'Unternehmen Region' [a program to support
cooperation aimed at innovation on a local level].
Immungenetics AG is a company of innoveas AG (www.innoveas.com) and is
certified according to the quality management system DIN EN ISO 9001 as
well as DIN EN ISO 13485.
End of Media Release
---------------------------------------------------------------------
02.09.2011 Dissemination of a Press Release, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
138046 02.09.2011
Themen in dieser Pressemitteilung:
immungenetics-ag-immungenetics-ag-sets-up-a-cooperation-with-prof-jens-pahnke
m-d-ph-d
e-f-n
for-the-further-development-of-the-new-alzheimer-s-gene
Unternehmensinformation / Kurzprofil:
" alt="Zimtu Capital Corp. Completes Transaction for Graphite Projects">
" alt="Legend Gold Corp. Acquires Key Gold Property in Republic of Mali, West Africa">
Datum: 02.09.2011 - 08:27 Uhr
Sprache: Deutsch
News-ID 61875
Anzahl Zeichen: 6291
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 473 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Immungenetics AG: Immungenetics AG sets up a cooperation with Prof. Jens Pahnke, M.D. Ph.D., E.F.N., for the further development of the new 'Alzheimer's gene'"
steht unter der journalistisch-redaktionellen Verantwortung von
Immungenetics AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
